BiotechTube

ABBV-319

Phase 1Recruiting
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dry Eye Syndrome

Conditions

Dry Eye Syndrome, Systemic Lupus Erythematosus

Trial Timeline

Aug 26, 2025 → Mar 1, 2029

NCT ID
NCT06977724

About ABBV-319

ABBV-319 is a phase 1 stage product being developed by AbbVie for Dry Eye Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06977724. Target conditions include Dry Eye Syndrome, Systemic Lupus Erythematosus.

What happened to similar drugs?

20 of 20 similar drugs in Dry Eye Syndrome were approved

Approved (20) Terminated (4) Active (0)
✅high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibeYuhanApproved
✅Telmisartan 40mg + Rosuvastatin 20mg + Telmisartan 80mg + Rosuvastatin 20mg + Telmisartan 40mg, 80 mg + Rosuvastatin 20mgYuhanApproved
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
✅PrasugrelDaiichi SankyoApproved
✅30-day DAPT + Guideline-directed therapyDaiichi SankyoApproved
✅Gabapentin enacarbilAstellas PharmaApproved
✅Ramosetron + PlaceboAstellas PharmaApproved

Hype Score Breakdown

Clinical
6
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT06977724Phase 1Recruiting
NCT05512390Phase 1Recruiting

Competing Products

20 competing products in Dry Eye Syndrome

See all competitors
ProductCompanyStageHype Score
NEX-18a injection + Azacitidine InjectionNanexa ABPhase 1
23
NAV5001 + DaTscanNavidea BiopharmaceuticalsPhase 3
22
JSP191Jasper TherapeuticsPhase 1
11
Humanized anti-CD117 Monoclonal Antibody (JSP191)Jasper TherapeuticsPhase 1
15
Tildacerfont + PlaceboSpruce BiosciencesPhase 2
17
agenT-797MiNK TherapeuticsPhase 1
19
SomatropinEli LillyPhase 3
40
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase IIGT BiopharmaPhase 1/2
14
CTH120Connecta TherapeuticsPhase 1
19
CrovalimabChugai PharmaceuticalPhase 3
44
RAY121Chugai PharmaceuticalPhase 1
36
Crovalimab + Placebo + Intravenous immunoglobulin therapyChugai PharmaceuticalPhase 3
32
CrovalimabChugai PharmaceuticalPhase 3
44
RAY121Chugai PharmaceuticalPhase 1
36
YH14659 + clopidogrel & aspirinYuhanPhase 1
29
high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibeYuhanApproved
43
YH14659 + clopidogrel & aspirinYuhanPhase 1
29
Telmisartan 40mg + Rosuvastatin 20mg + Telmisartan 80mg + Rosuvastatin 20mg + Telmisartan 40mg, 80 mg + Rosuvastatin 20mgYuhanApproved
35
Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
43
clopidogrel + prasugrelDaiichi SankyoPhase 1
21